Order Article Reprints

Hou Z, Lin S, Du T, Wang M, Wang W, You S, Xue N, Liu Y, Ji M, Xu H, et al. Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals. 2025; 18(9):1355. https://doi.org/10.3390/ph18091355

Hou, Zhenyan, Songwen Lin, Tingting Du, Mingjin Wang, Weida Wang, Shen You, Nina Xue, Yichen Liu, Ming Ji, Heng Xu, and et al. 2025. "Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749" Pharmaceuticals 18, no. 9: 1355. https://doi.org/10.3390/ph18091355

Hou, Z., Lin, S., Du, T., Wang, M., Wang, W., You, S., Xue, N., Liu, Y., Ji, M., Xu, H., & Chen, X. (2025). Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals, 18(9), 1355. https://doi.org/10.3390/ph18091355